Fig. 4From: In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity mattersProphylactic approach. Mice received repetitive local applications of the Mlh1−/− A7450 T1 M1 and Mlh1−/− 328 vaccine, respectively (10 mg/kg bw, s.c., n = 9 mice/group). Control mice were left untreated (n = 15 mice). a Kaplan–Meier survival curve analysis. *p < 0.001 A7450 T1 M1 vs. control; Log-rank (Mantel–Cox) test. b Immune phenotyping of peripheral blood was done before and during the course of vaccination until the experimental endpoint. Samples were analyzed by flow cytometry on a FACSVerse™, data analyses were performed using BD FACSuite software. Given are the % numbers of positive cells measured upon gating on viable cellsBack to article page